In U.S. tissue regulation, minimally manipulated means processing has not altered the tissue or cells’ relevant characteristics. For structural tissue, these are the original characteristics related to reconstruction, repair, or replacement. For cells or nonstructural tissue, they are the relevant biological characteristics.Regulatory considerations human cells tissues and cellular and tissue based products minimalPart 1271 The term describes processing; it does not, by itself, establish FDA approval, safety, or effectiveness.
If a clinic uses this phrase, ask what tissue it starts with, how it processes it, and which characteristics remain intact. FDA’s July 2020 guidance gives examples for different tissues.Regulatory considerations human cells tissues and cellular and tissue based products minimal The Ryoncil approval record, discussed below, illustrates a separate question: what evidence supports approval of a specific cell therapy?Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host

Key regulatory facts
| Data point | What it is | Why it matters for this question |
|---|---|---|
| 2 definitions | 21 CFR 1271.3(f) has one test for structural tissue and one for cells or nonstructural tissuesRegulatory considerations human cells tissues and cellular and tissue based products minimalPart 1271 | The same processing step can have a different meaning for bone or fat than for blood-forming cells |
| 4 criteria | 21 CFR 1271.10(a) lists minimal manipulation, homologous use, combination, and systemic-effect conditionsRegulatory considerations human cells tissues and cellular and tissue based products minimalPart 1271 | Failure on any one criterion can move a product into drug, device, or biological-product review |
| 8 structural-tissue groups | FDA lists bone, skin, amniotic membrane and umbilical cord, blood vessel, adipose tissue, articular and non-articular cartilage, and tendon or ligamentRegulatory considerations human cells tissues and cellular and tissue based products minimal | The structural group is wide, and it includes fat |
| 54 patients, 30% complete and 41% partial response at day 28 | FDA approval basis for Ryoncil, the first FDA-approved MSC therapy, in pediatric steroid-refractory acute graft-versus-host diseaseFda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host | It lists the population, dose, route, endpoint, and safety record behind an approval, not just a processing label |
Why clinics mention it
A claim of minimal manipulation addresses only one of the four criteria in 21 CFR 1271.10(a). It does not settle the other three: homologous use, combination with other articles, and systemic-effect or living-cell-metabolism conditions.Regulatory considerations human cells tissues and cellular and tissue based products minimalPart 1271
HCT/P is FDA’s abbreviation for human cells, tissues, and cellular and tissue-based products. To be regulated solely under section 361 of the Public Health Service Act and Part 1271, an HCT/P must meet all four criteria below; that route does not require FDA premarket approval.Part 1271
- It is minimally manipulated.
- It is intended for homologous use only.
- It is not combined with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent that does not raise new safety concerns.
- It either has no systemic effect and does not depend on living-cell metabolism for its primary function, or, if either applies, it is for autologous use, allogeneic use in a first- or second-degree blood relative, or reproductive use.
If any criterion fails without an available exception, FDA regulates the product as a drug, device, or biological product, so premarket review applies.Regulatory considerations human cells tissues and cellular and tissue based products minimalPart 1271
Two tests, not one
Your answer changes with the starting material, so check which group your treatment falls in:
| Starting material | What FDA looks at | Examples of the material |
|---|---|---|
| Structural tissue | Did processing alter the original relevant characteristics tied to reconstruction, repair, or replacement?Regulatory considerations human cells tissues and cellular and tissue based products minimal | Bone, skin, amniotic membrane, blood vessel, adipose tissue, cartilage, tendon, ligament |
| Cells or nonstructural tissue | Did processing alter the relevant biological characteristics of the cells or tissues?Regulatory considerations human cells tissues and cellular and tissue based products minimal | Hematopoietic stem and progenitor cells, lymph nodes, thymus, parathyroid, peripheral nerve, pancreatic tissue, reproductive cells |
Structural tissues do physical work. They support, cover, cushion, connect, or work as a barrier or conduit. For cells and nonstructural tissues, relevant functions can include blood formation, immune activity, and hormone production. For structural tissue, FDA examines strength, flexibility, cushioning, covering, compressibility, and response to friction and shear. For cells, FDA examines differentiation and activation state, proliferation potential, and metabolic activity.Regulatory considerations human cells tissues and cellular and tissue based products minimal
What counts as processing
To answer whether your treatment is minimally manipulated, include every manufacturing step, not just the final injection. Processing includes testing for microorganisms, sterilization, preservation, cutting, grinding, shaping, culturing, enzymatic digestion, and decellularization.Regulatory considerations human cells tissues and cellular and tissue based products minimal Donor screening and testing, storage, labeling, packaging, and distribution do not count as processing.Part 1271 FDA reviews processing as a whole. A simple step at the bedside does not settle the question when an earlier laboratory step changed the key characteristics.Regulatory considerations human cells tissues and cellular and tissue based products minimal
What still counts
Each case depends on the exact method and whether the named characteristic stayed the same:Regulatory considerations human cells tissues and cellular and tissue based products minimal
- Shaping bone into dowels, screws, or pins when strength and resistance to compression are preserved.
- Grinding bone into chips or particles when the characteristics tied to supporting bodily structures are preserved.
- Preserving and packaging amniotic membrane in sheets when physical integrity, tensile strength, and elasticity are preserved.
- Processing skin by mechanical meshing and cryopreservation into meshed sheets when its role as a protective covering is preserved.
- Selecting hematopoietic stem and progenitor cells from mobilized peripheral blood to obtain a higher concentration for transplantation, when the ability to repopulate marrow by self-renewal and differentiation is not altered.
A small change in size or shape is not automatically minimally manipulated. The test stays the same: did the original relevant characteristics change?Regulatory considerations human cells tissues and cellular and tissue based products minimal
What no longer counts
FDA’s guidance describes the following examples as generally more than minimally manipulated because processing changes relevant characteristics.Regulatory considerations human cells tissues and cellular and tissue based products minimal
- Exposing bone to acid at high temperature to demineralize it and form a gel, which changes strength and support characteristics.
- Grinding and freeze-drying amniotic membrane into particles, which changes barrier integrity, strength, and elasticity.
- Grinding sheets of fascia lata into particles, which changes strength, flexibility, and sheet-like structure.
- Removing cells from adipose tissue to leave only decellularized matrix, which changes bulk and lipid-storage characteristics tied to cushioning and support.
- Culturing hematopoietic stem and progenitor cells to produce terminally differentiated cells, which changes multipotency and self-renewal capacity.
- Incubating selected cord-blood cells in culture media with growth factors to produce large numbers of cells for long-term marrow repopulation, which changes lineage, activation, and proliferation characteristics.
FDA guidance describes two culture cases that fail the test. Growth under special conditions can change differentiation state, activation, proliferation potential, and protein expression.Regulatory considerations human cells tissues and cellular and tissue based products minimal
Fat and stromal vascular fraction
Adipose tissue counts as structural tissue because its bulk and lipid-storage capacity provide cushioning and support. Fat contains several cell types, but that fact does not move it to another group. A manufacturer recovers fat by liposuction and then breaks it down with enzymes or mechanical force to isolate cellular components, with or without later culture. The isolated cell mixture is commonly called stromal vascular fraction (SVF). FDA guidance treats that work as generally more than minimally manipulated because it breaks down fat cells and the surrounding structure that provides cushioning and support.Regulatory considerations human cells tissues and cellular and tissue based products minimal If that processing fails the minimal-manipulation criterion, the product cannot qualify for the section-361-only route under 21 CFR 1271.10(a).Part 1271 Approval, safety, and benefit still need a separate product- and indication-specific review.
Why approval looks different
If you wonder what a yes looks like instead of a processing label, Ryoncil shows the difference. It is an allogeneic bone-marrow-derived mesenchymal stromal cell therapy. The United States approved it on 18 December 2024 for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older after allogeneic blood stem-cell transplantation.Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host Cultured MSC products of this kind are generally more than minimally manipulated, so Ryoncil went through premarket approval rather than the tissue-only route.Regulatory considerations human cells tissues and cellular and tissue based products minimalApproved cellular and gene therapy products
FDA evaluated safety and effectiveness in a multicenter, single-arm study involving 54 pediatric participants, with no comparison group. The treatment schedule was intravenous Ryoncil twice weekly for 4 weeks, totaling 8 infusions. Investigators used International Blood and Marrow Transplantation Registry severity criteria to characterize disease at baseline. The main effectiveness assessment concerned the rate and duration of response at day 28. Sixteen participants (30%) had a complete response and 22 participants (41%) had a partial response at day 28. Participants with a partial or mixed response received additional once-weekly infusions for 4 more weeks.Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host
The most common adverse reactions were infections, fever, hemorrhage, edema, abdominal pain, and hypertension. The product information also warns about hypersensitivity and acute infusion reactions, transmission of infectious agents, and ectopic tissue formation. Treatment requires premedication with corticosteroids and antihistamines, monitoring during infusion, and stopping the infusion when reactions occur such as breathing difficulty, low blood pressure, fever, rapid breathing, bluish skin or lips, or low blood oxygen. It is contraindicated with known hypersensitivity to dimethyl sulfoxide or porcine and bovine proteins.Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host
The approval is specific to Ryoncil and its labeled indication; it does not validate other MSC preparations or uses. A day-28 response is not a guarantee of lasting benefit, and a single-arm study cannot establish comparative effectiveness. The figures above do not support extrapolation to arthritis, neurologic disease, lung disease, or anti-aging treatment.Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host FDA’s consumer information dated 8 April 2024 describes unapproved regenerative products marketed for such uses; that page is not a substitute for checking a particular product’s current approval and indication.Important patient and consumer information about regenerative medicine therapies
Why one test is not enough
Minimal manipulation and homologous use answer different regulatory questions. Homologous use means repair, reconstruction, replacement, or supplementation with an HCT/P that performs the same basic function in the recipient as in the donor.Part 1271Regulatory considerations human cells tissues and cellular and tissue based products minimal Take fat as the example. Using adipose tissue to fill a facial void for cushioning can qualify as homologous use. Using fat-derived cells to regrow cartilage, treat joint disease, or limit autoimmunity in multiple sclerosis generally does not qualify, because those are not basic functions of fat.Regulatory considerations human cells tissues and cellular and tissue based products minimal
The combination and systemic-effect rules can also trigger premarket review. Addition of another article beyond the narrow allowances counts. A systemic effect or dependence on living-cell metabolism for the primary function also matters, unless the autologous, specified blood-relative, or reproductive-use conditions apply. Processing alone cannot keep the product in the tissue-only path when those conditions fail.Regulatory considerations human cells tissues and cellular and tissue based products minimalPart 1271
A separate same-surgical-procedure exception exists in 21 CFR 1271.15(b), but it has its own scope and conditions.Part 1271Framework regulation regenerative medicine products Rinsing or cleansing alone does not show that an establishment qualifies.
What it never promises
When you search what minimally manipulated means, rule out these common misunderstandings:
- Approval is separate. A minimally manipulated label does not show that a product is approved for the disease being treated. FDA’s consumer warning describes unapproved regenerative products marketed for orthopedic, neurologic, cardiac, pulmonary, and anti-aging uses.Important patient and consumer information about regenerative medicine therapies
- Safety and benefit are separate. FDA consumer information lists reported problems after unapproved regenerative products, including infections, blindness, tumor formation, neurologic events, unwanted immune responses, cells growing in the wrong place, and contamination during preparation.Important patient and consumer information about regenerative medicine therapies
- Natural or untouched is the wrong test. Centrifugation, filtration, and cryopreservation can fall in either category depending on their effect. Enzymatic digestion and culture are processing, not just handling.Regulatory considerations human cells tissues and cellular and tissue based products minimal
- Same-day timing settles nothing. Timing does not decide the definition. FDA assesses all processing steps together under 21 CFR 1271.3(ff).Part 1271
- One product’s classification does not automatically apply to another. The assessment follows the specific tissue, processing, labeling, and intended use.Regulatory considerations human cells tissues and cellular and tissue based products minimalPart 1271
A trials-database listing does not make marketing lawful. An FDA establishment registration does not either.Important patient and consumer information about regenerative medicine therapies
How Japan handles it
The definition discussed here is the U.S. definition under 21 CFR Part 1271.Part 1271 Japan uses a different system. Commercial regenerative products receive review under the Pharmaceuticals and Medical Devices Act.0003 A separate framework under the Act on the Safety of Regenerative Medicine covers relevant medical practice and research, with provision-plan review and submission involving certified committees and the e-Saiseiiryo public-plan system.Index
A Japanese clinic plan filing is not a product approval. An American tissue-product analysis does not transfer to Japan.0003Index Ask which framework the clinic means and request the exact product or plan name, indication, and documents in writing.
What to ask your clinic
Use your original question as a checklist. Ask for specifics, not slogans:
- Which tissue did you start with, and do you treat it as structural or cellular in your analysis?
- What were all the processing steps, including digestion, separation, culture, freezing, and storage?
- Which original or biological characteristics did you assess, and what testing shows that they did not change?
- What is the intended homologous use, stated in terms of the donor tissue’s basic function?
- Is the product combined with anything besides water, crystalloids, or an allowed storage or sterilizing agent?
- Are you claiming minimal manipulation plus homologous use to avoid premarket review, or do you hold an approval or an active investigational authorization for this use?
- What are the known risks, contraindications, follow-up plan, and arrangements for complications after travel?
A clear answer names the tissue, the steps, the characteristics tested, and the regulatory route. Vague words such as pure, natural, or same-day cells prove nothing.
A practical document check
Use the processing description in a consent form or treatment proposal, rather than a slogan, as your starting point. For a concrete example, compare FDA’s bone-processing examples: shaping bone into a screw can preserve strength and resistance to compression, whereas processing bone into a gel can alter its supporting characteristics. The word “processed” alone does not distinguish the two.Regulatory considerations human cells tissues and cellular and tissue based products minimal
For your own documents, make three entries: starting tissue, every processing step, and intended use. If a proposal says only “your own cells, prepared the same day,” those words leave the actual processing and relevant characteristics unanswered. Ask the provider to fill those gaps in writing and explain homologous use separately. This is an illustrative document-checking exercise, not a patient case or a regulatory determination.
If a clinic mentions minimal manipulation for your case, bring the exact product name, processing steps, and intended use to your inquiry.
Ask which documents are needed for an inquiry. Have a qualified treating clinician explain the proposed treatment’s risks, alternatives, and follow-up before you decide about travel.
Bottom line
Minimally manipulated means the relevant structural or biological characteristics survived processing. It is one of four criteria for the U.S. section-361-only route, not a safety rating or proof that a treatment works.Regulatory considerations human cells tissues and cellular and tissue based products minimalPart 1271
Before deciding on treatment, ask for the starting material, complete processing steps, intended use, and applicable regulatory documents. Discuss them with a qualified clinician who has reviewed your records. This article explains terminology and is not medical advice.




